Trial Profile
A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms COTSOM
- 15 Dec 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 15 Dec 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 15 Dec 2017 Status changed from recruiting to active, no longer recruiting.